AddLife stock
Price history
−1.67% over the period1 year: from kr 179.60 (November 20, 2025) to kr 176.60 (November 20, 2026), −1.67%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | kr 176.60 |
| October 30, 2026 | kr 182.30 |
| September 30, 2026 | kr 172.00 |
| August 31, 2026 | kr 167.50 |
| July 31, 2026 | kr 161.60 |
| June 30, 2026 | kr 163.40 |
| May 29, 2026 | kr 148.90 |
| April 30, 2026 | kr 142.90 |
| March 31, 2026 | kr 139.50 |
| February 27, 2026 | kr 154.20 |
| January 30, 2026 | kr 136.50 |
| December 30, 2025 | kr 159.10 |
| November 28, 2025 | kr 189.00 |
| November 20, 2025 | kr 179.60 |
At a glance
The company
Supplies instruments, equipment, consumables and reagents for medical care, research, diagnostics and laboratory analysis, plus medical devices for surgery and healthcare
Latest results
Quarter to September 30, 2026 · EPS kr 1.05 (estimate kr 0.87)
TickerLandia's take on AddLife
- Priced as usual relative to earnings: P/E on the latest fiscal year 38 vs a median of 35 over its last 10 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 34 vs 25 (+33%) in a group of 9.
- Strong point: Earnings stability (59/100 in its group). Weak point: Financial strength (20/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−8.40% from the 52-week high
Analysts · 3 analysts
Average targetkr 205.75+16.51% vs. price
Buy 2 · Hold 1 · Sell 0
TickerLandia Fingerprint: AddLife
Compared with similar companies: very low financial strength.
Financials and price compared with 34 companies in the medical instruments & supplies industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Priceaverage54
How much it costs relative to what it produces.
Metric Value Position in group EV/EBITDA 17.1 54 Price/sales 2.01 28 P/E (trailing 12 months) 33.5 45 Forward P/E 55.5 90 Price/book 3.61 54 Profitabilitylow37
How much it earns on revenue and capital.
Metric Value Position in group Net margin 6.0% 37 ROE 11.5% 57 Gross margin 38.7% 25 Operating margin 8.9% 28 ROA 4.5% 40 Earnings stabilityaverage59
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 2.8% 54 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Growthaverage55
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +4.75% 40 Revenue growth (year over year) +7.00% 57 Earnings growth (year over year) +57.90% 67 Financial strengthvery low20
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage 4.21 32 Debt/equitycounts in reverse: lower means more financial strength 0.86 23 Current ratio 0.65 1 Net debt/EBITDAcounts in reverse: lower means more financial strength 2.79 23 Dividendlow31
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 10 years 29 Payout ratio 28.5% 35 Dividend yield 0.8% 28 Market momentumaverage58
How the stock has moved compared with the market.
Metric Value Position in group 1-year return −1.67% 34 Distance from 200-day average +11.12% 82 Riskaverage50
How much the price swings.
Metric Value Position in group Volatility (60 days) 24.0% 35 Maximum drawdown (12 months) 28.8% 65
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
AddLife is priced as in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), AddLife's P/E today is 38.5, in line with the median of its last 10 fiscal years (35.4; between 26.9 and 70.2 from 2016 to 2025). AddLife's P/E (trailing 12 months): 33.5, +33% against the median of a group of 9 similar companies (25.1).
Compared with 9 similar companies
| Metric | AddLife | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 33.5 | Middle | |
| Forward P/E | 55.5 | High | |
| Operating margin | 8.9% | Middle | |
| ROE | 11.5% | Middle | |
| Debt/equity | 0.86 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: AddLife. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
kr 2.6B
Latest quarter · Q3 2026
Net income
kr 127M
Latest quarter · Q3 2026
Quarterly net margin
4.9%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- kr 21.52B
- P/E
- 33.5
- EPS
- kr 5.27
- Volume
- 100.14K
- Daily trading
- €2.83M
- Dividend yield
- 0.85%
- Last ex-dividend on May 7, 2026
How AddLife is changing
All resultsRevenue grew 14.6% a year on average over the last 5 years
Shares outstanding up 8.2% in 5 years
Revenue has grown for 9 fiscal years in a row
Returns
AddLife returns with dividends
kr 1,000 invested in AddLife 5 years ago, on November 22, 2021, would be worth kr 527 today with dividends reinvested: −47.29% in total, −12.04% per year. On price alone it would be kr 507 (−49.28%).
| Period | AddLife | kr 1,000 becomes |
|---|---|---|
| 1 month | −4.64% | kr 954 |
| 6 months | +17.73% | kr 1,177 |
| Year to date | +11.00% | kr 1,110 |
| 1 year | −0.64% | kr 994 |
| 3 years | +106.42% | kr 2,064 |
| 5 years | −47.29% | kr 527 |
| 10 years | +503.51% | kr 6,035 |
From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment
The chart in detail
AddLife: technical analysis
AddLife is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 54.7% below its all-time closing high (kr 390.00, September 17, 2021).
- Trend
- Upward
- RSI (14 sessions)
- 44
- Between 30 and 70
- vs 200-session average
- +11.12%
Active signals
Close below the low of the previous 20 sessions.
The price is moving in an unusually narrow range compared with the last year.
since November 10, 2026
Support and resistance
Price areas where AddLife has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistancekr 189.20+7.13%2 touches, last on November 5, 2026
- Resistancekr 177.30+0.40%3 touches, last on November 3, 2026
- Last pricekr 176.60
- Supportkr 174.00−1.47%2 touches, last on July 16, 2026
- Supportkr 167.78−5.00%4 touches, last on October 8, 2026
- Supportkr 154.12−12.73%6 touches, last on September 10, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 24.0%
- Largest fall in the last year
- −28.78%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
AddLife: seasonality
Average monthly price change over 11 years
Over the last 11 years, the strongest month for AddLife has been April: +10.93% on average, positive in 9 years out of 11. The weakest has been September: −5.12% on average, positive in 2 years out of 11. November, the current month, has been positive in 6 years out of 10 (+5.70% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −0.19% | +2.27% | 8 of 10 |
| February | +2.49% | +5.10% | 6 of 10 |
| March | −1.91% | −7.30% | 4 of 10 |
| April | +10.93% | +8.01% | 9 of 11 |
| May | +6.57% | +6.56% | 10 of 11 |
| June | −0.10% | +2.33% | 6 of 11 |
| July | +4.98% | +9.20% | 6 of 11 |
| August | +3.28% | +3.65% | 8 of 11 |
| September | −5.12% | −3.24% | 2 of 11 |
| October | +0.20% | +2.01% | 7 of 11 |
| November | +5.70% | +1.01% | 6 of 10 |
| December | +2.03% | +1.95% | 7 of 10 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
AddLife and its competitors
Laboratory analytical instruments, microscopes, consumables and reagents, together with medical devices for surgery, orthopaedics, endoscopy and wound care, form the core of AddLife's offering. Its Labtech segment serves diagnostics and biomedical research, with products spanning microbiology, clinical chemistry, molecular biology, immunology and veterinary diagnostics, and it also provides training for customers. The Medtech segment covers critical care, ophthalmology, healthcare IT and assistive devices for the elderly and disabled.
- Headquarters
- Stockholm, Sweden
- Employees
- 2,428
- Founded
- 1906
- Chief executive
- Fredrik Dalborg
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| AddLifeALIF.B | $2.11B | 8.9% | 33.5 | +17.73% |
| Bonesupport HoldingBONEX | $2.03B | 25.5% | 78.1 | +25.60% |
| OttobockOBCK | $2.68B | 18.7% | 19.0 | −31.33% |
| Carl Zeiss MeditecAFX | $3.07B | 7.2% | 23.3 | +24.32% |
| Tecan GroupTECN | $3.58B | 4.9% | — | +64.44% |
| GerresheimerGXI | $1.19B | 1.6% | — | +21.95% |
Same industry or related industries, similar size. Compare AddLife with its competitors · Full profile
